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Effective gene delivery to the central nervous system 
(CNS) is vital for development of novel gene therapies 
for neurological diseases. Adeno-associated virus (AAV) 
vectors have emerged as an effective platform for in vivo 
gene transfer, but overall neuronal transduction efﬁ-
ciency of vectors derived from naturally occurring AAV 
capsids after systemic administration is relatively low. 
Here, we investigated the possibility of improving CNS 
transduction of existing AAV capsids by genetically fus-
ing peptides to the N-terminus of VP2 capsid protein. 
A novel vector AAV-AS, generated by the insertion of a 
poly-alanine peptide, is capable of extensive gene trans-
fer throughout the CNS after systemic administration in 
adult mice. AAV-AS is 6- and 15-fold more efﬁcient than 
AAV9 in spinal cord and cerebrum, respectively. The 
neuronal transduction proﬁle varies across brain regions 
but is particularly high in the striatum where AAV-AS 
transduces 36% of striatal neurons. Widespread neuro-
nal gene transfer was also documented in cat brain and 
spinal cord. A single intravenous injection of an AAV-AS 
vector encoding an artiﬁcial microRNA targeting hun-
tingtin (Htt) resulted in 33–50% knockdown of Htt 
across multiple CNS structures in adult mice. This novel 
AAV-AS vector is a promising platform to develop new 
gene therapies for neurodegenerative disorders.
Received 2 August 2015; accepted 16 December 2015; advance online  
publication 26 January 2016. doi:10.1038/mt.2015.231
INTRODUCTION
Recombinant AAV vectors have emerged as the vehicle of choice 
for in vivo gene transfer to the central nervous system (CNS) 
due to efficient transduction of neurons1 and other cell types of 
therapeutic relevance.2–4 AAV vectors are nonpathogenic and 
have a relatively low immunogenic and cytotoxicity profile, and 
importantly have been shown to direct stable long-term transgene 
expression in the brain of large animal models5,6 and humans.7,8
The first generation of AAV gene therapy for neurological dis-
eases is based on intracranial injections into target structures and 
has proven effective in numerous mouse and large animal models 
of neurodegenerative diseases.6,9 The efficacy of intraparenchy-
mal infusion of AAV vectors for CNS gene therapy has improved 
through the identification of new AAV capsids with better trans-
duction and distribution properties,10–12 as well as the use of con-
vection-enhanced delivery techniques13 and magnetic resonance 
imaging-guided infusion.14 Several clinical trials have been con-
ducted or are currently underway to test intracranial injection of 
AAV vectors for different neurodegenerative diseases.7,8,15–18
There is an increasing recognition that many neurodegenera-
tive diseases affect more than a single structure in the CNS and 
dominant phenotypic manifestations driven by a particular struc-
ture may be a reflection of different kinetics of disease progres-
sion across neuronal populations. Therapeutic efficacy in these 
disorders will therefore depend heavily on efficiently targeting 
all structures involved in disease pathophysiology. Huntington’s 
disease (HD) is an example of an evolving perspective on tar-
get structures for therapeutic intervention. A recent study using 
transgenic HD mice showed that combined deletion of mutant 
huntingtin (Htt) in cortical and striatal neurons is necessary to 
ameliorate all behavioral deficits and neurodegeneration, while 
deletion in each population individually resulted only in partial 
effects.19 The implication is that transformative clinical outcomes 
in a disease such as HD may only be achieved when therapeutic 
interventions are effective across multiple brain structures. The 
same case could be made for numerous other neurodegenera-
tive diseases with diverse neuropathological features. Achieving 
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global gene transfer to the CNS using intraparenchymal injections 
is a daunting, perhaps impossible task, especially considering the 
complex geometry and volume of the cortices. Transport of AAV 
vectors from the injection site to axonally connected structures 
can expand the therapeutic reach of local interventions,20–23 but 
massive doses may be needed to achieve significant transduction 
and coverage in distal structures.
The discovery that AAV9 can cross the blood–brain barrier 
(BBB) after intravascular delivery in neonatal and adult animals 
was a critical step for AAV-based CNS gene therapy.24 Other AAV 
capsids such as AAVrh8 and AAVrh10 were subsequently shown 
to share this property.25,26 Several studies have demonstrated the 
therapeutic efficacy of intravenously delivered AAV9 vectors in 
animal models of spinal cord motor neuron degeneration27,28 and 
neurometabolic disorders.29–31 However, while intravascular infu-
sion of AAV9 is efficient for gene delivery to spinal cord motor 
neurons,24,26 dorsal root ganglia,32 and enteric nervous system 
neurons,33,34 the vast majority of transduced cells in the brain 
are either glia or endothelial cells with sparse neuronal trans-
duction.24,25 The tropism of AAV9 to spinal cord motor neurons, 
which is consistent across species,24,32,35 contributed to the pheno-
typic rescue of spinal muscular atrophy mice treated at postnatal 
day 2 (PND2) by systemic infusion of an AAV9 vector encoding 
survival motor neuron (SMN) protein.27 However, the effective-
ness of AAV9-SMN treatment declined rapidly with age and infu-
sion at PND5 showed only a modest survival benefit and no effect 
by PND10.27 The reduced therapeutic benefit with age correlated 
with declining transduction of spinal cord motor neurons at older 
ages when most transduced cells were glia.27 While systemic deliv-
ery of AAV9 vectors has proven exceptionally efficient in mouse 
models of Canavan disease treated as late as PND2031 and in adult 
models of lysosomal storage diseases,29,30 therapeutic efficacy in 
these diseases is likely less dependent on neuronal transduction. 
In Canavan disease, it is possible that any transduced cell over-
expressing aspartoacylase may function as a metabolic sink for 
N-acetyl aspartic acid.31 In lysosomal storage disorders, there is 
a cross correction mechanism in which AAV-transduced cells 
secrete large quantities of functional enzyme that is taken up 
and correctly targeted to the lysosomes of enzyme-deficient cells. 
Therefore, disperse N-acetyl aspartic acid metabolic sinks or 
sources of functional lysosomal enzymes throughout the CNS, 
regardless of phenotype, are likely to exert a powerful therapeu-
tic effect. Most neurological diseases, however, are unlikely to 
benefit from such mechanisms and will require efficient neuro-
nal gene transfer to change the course of disease progression. 
There is therefore a clear need for AAV capsids with improved 
neuronal transduction properties to develop the next generation 
of gene therapies for multifocal neurodegenerative diseases. AAV 
capsids with novel or enhanced properties have been developed 
through directed evolution,36–39 mutational scanning40 and display 
of targeting peptides on AAV capsids.41–43 Here, we investigated 
whether incorporating additional targeting modules through 
insertion of different peptides into the capsid of an AAV9 variant 
would increase CNS gene transfer efficiency.
RESULTS
Insertion of poly-alanine peptide in AAV9.47 capsid 
enhances neuronal gene transfer in adult mice
We chose AAV9.47 as the capsid in which to test our peptide-
grafting approach as this quadruple mutant of AAV9 (S414N, 
G453D, K557E, T582I) has comparable CNS gene transfer prop-
erties to AAV9 but decreased tropism to liver44 (Supplementary 
Figure S1). Peptides were grafted on the AAV9.47 capsid sur-
face via genetic fusion to the N-terminus of VP2 using a pre-
viously described approach45 (Figure 1a). Unexpectedly, one 
of the control vectors used for this screen, a peptide-modified 
AAV9.47 vector carrying a string of 19 alanines in the VP2 
capsid protein, designated as AAV-AS (Figure 1b), showed a 
remarkable increase in CNS transduction efficiency compared 
to AAV9 (Figure 2a) after systemic delivery in 6–8-week-old 
C57BL/6 mice (Figure 2a). AAV-AS vector transduced diverse 
neuronal populations, glia and endothelia throughout the brain 
and spinal cord, including extensive transduction of neurons 
in motor cortex and striatum (Figure 2b). We also observed 
efficient transduction of granule cells in the dentate gyrus as 
well as motor neurons and interneurons in the spinal cord 
(Figure 2b). The identity of GFP-positive cells with neuronal 
morphology in cortex, striatum, and spinal cord was confirmed 
Figure 1  Construction of AAV-AS vector. (a) Illustration of packaging strategy. VP1 and VP3 are expressed separately (top) from VP2 fused with 
peptide (below). (b) Schematic diagram of VP2 capsid protein showing insertion site of AS peptide and G4S linker.
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by colocalization of GFP and NeuN (Figure 2c). GFP-positive 
neurons in the striatum were shown to be DARPP32-positive 
medium spiny neurons (Figure  2c). Neuronal transduction 
was apparent in many brain regions of AAV-AS-injected mice 
with the exception of thalamus and hypothalamus where only 
sparse transduction was observed (Supplementary Figure S2). 
AAV-AS also transduced glial fibrillary acidic protein (GFAP)-
positive astrocytes (Figure 2c), oligodendrocytes in the corpus 
callosum and Bergmann glia in the cerebellum (Supplementary 
Figure S2). The transduction profile of AAV9 was limited to glial 
cells and endothelia in most CNS regions analyzed (Figure 2b 
and Supplementary Figure S2).
Western blot analysis of AAV preparations confirmed incor-
poration of the chimeric poly-alanine VP2 protein in the AAV-AS 
capsid (Figure 3a). Quantification of GFP-positive neurons 
revealed AAV-AS transduced as many as 36% of striatal neurons 
compared to only 0.45% by AAV9. In contrast, the increase in 
transduced thalamic neurons was more modest (Figure 3b). The 
CNS transduction efficiency of AAV-AS vector was also reflected 
in its biodistribution profile. More vector genomes were found in 
Figure 2 Central nervous system transduction proﬁle of AAV-AS vector after vascular infusion in adult mice. (a) Overview of GFP distribution in brain 
and spinal cord in AAV-AS and AAV9 injected mice (5 × 1011 vg/mouse). Representative images of coronal brain sections located in relation to bregma at 
+0.5, −0.5, and −1.80 mm, and cervical spinal cord (left to right) are shown. (b) Transduction of neuronal populations in different brain regions. Black 
arrows indicate examples of GFP-positive neurons identiﬁed by morphology. Bar = 50 μm. (c) Phenotype of transduced cells was identiﬁed by double 
immunoﬂuorescence staining with antibodies to GFP, pan-neuronal marker NeuN, striatal medium spiny neuron marker DARPP32 or astrocyte marker 
glial ﬁbrillary acidic protein (GFAP). Neuronal transduction in spinal cord was examined in sections stained for GFP and NeuN. The large size and mor-
phology of GFP-positive neurons in the ventral spinal cord suggest a motor neuron identity. White arrows indicate examples of GFP-positive neurons. 
Bar = 10 μm.
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the cerebrum and spinal cord of AAV-AS-injected animals com-
pared to AAV9 (15-fold and 6-fold, respectively) (Figure 3c). These 
findings were corroborated by comparable increase in GFP pro-
tein in cerebrum and spinal cord (Figure 3d). The increased gene 
transfer efficiency for AAV-AS vector compared to AAV9 appears 
to be restricted to CNS, as transduction of liver, muscle, lung, pan-
creas, and kidney was identical for both AAV vectors based on 
analysis of vector genome content (Figure 3e and Supplementary 
Figure S3) and GFP protein levels (Figure 3f). No inflammatory 
response characterized by reactive astrogliosis or microgliosis was 
observed due to AAV-AS infusion (Supplementary Figure S4).
As a first step to understand how the poly-alanine peptide 
enhances CNS transduction of AAV9.47, we carried out a cell cul-
ture study to determine whether it changes the capsid interaction 
with exposed galactose residues on cell surface glycans. Terminal 
N-linked galactose is the primary cell surface receptor for AAV9.46,47 
Binding studies in parental (Pro5) and sialic acid-deficient (Lec2) 
CHO cells showed no difference in receptor preference between 
AAV-AS, AAV9.47, and AAV9 vectors (Supplementary Figure S5).
AAV-AS transduces neurons throughout the cat brain 
after systemic administration
Next we assessed whether the neuronal transduction properties 
of AAV-AS are reproducible in cats as there are numerous mod-
els of neurodegenerative diseases in this species. Consistent with 
results in mice, AAV-AS transduced diverse neuronal populations 
across the cat brain and spinal cord, including neurons in cerebral 
cortex, striatum and reticular formation, Purkinje neurons in cer-
ebellum and motor neurons in the oculomotor nucleus located in 
ventral midbrain, spinal nucleus of the trigeminal nerve in brain-
stem and throughout the spinal cord (Figure 4a,b). Curiously, no 
endothelial and only sparse glial transduction was apparent in the 
cat brain in this study.
Widespread knockdown of Htt in CNS after systemic 
delivery of AAV-AS vector
Finally, we evaluated the therapeutic potential of AAV-AS vector 
for Huntington’s disease, a fatal autosomal dominant neurode-
generative disease caused by expansion of a CAG repeat in the 
Figure 3 Quantitative assessment of AAV-AS CNS transduction efﬁcacy. (a) Western blot analysis of capsid protein composition of AAV vectors 
(1 × 1010 vg/lane) showed the presence of VP1, VP2, and VP3 capsid proteins. The poly-alanine VP2 fusion protein of AAV-AS capsid (indicated by 
black arrow) has a higher molecular weight than VP2 protein. (b) Quantiﬁcation of percentage of GFP-positive neurons in striatum and thalamus 
of mice injected with AAV-AS-GFP or AAV9-GFP vectors. Data shown is mean ± SD (n = 4 biological replicates per group). (c) AAV vector genome 
content in cerebrum and spinal cords (n = 4 animals per group). Age-matched noninjected mice were included as controls (not shown). (d) Western 
blot analysis of GFP expression in cerebrum and spinal cord of two animals per group. Signal intensity of GFP was normalized to corresponding 
β-actin signal intensity for quantitative comparison. (e) AAV vector genome content in liver and skeletal muscle (quadriceps) (n = 4 animals per 
group). Data shown is mean ± SD. (f) Western blot analysis of GFP protein expression in liver and skeletal muscle (quadriceps). *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 by Student’s unpaired two-tailed t-test.
VP3
104 104
103
102
103
103
104
105
106
102
104
103
102102
VP2
VP1
50
40
2.0
1.0
0.0
Thalamus
AAV9
AAV-AS
AAV9
AAV9
AAV-AS
AAV-AS AAV9 AAV-AS AAV9 AAV9AAV-AS AAV-AS
0.5
1.5
30
20
10
Striatum
Cerebrum
Cerebrum
Spinal cord
Spinal cord
Liver
Liver
Muscle
Muscle
****
**
80.7
15.3
15.0 6.5 0.5 0.5
5.9
2.0
****
***
%
 tr
an
sd
uc
ed
 n
eu
ro
ns
v.
g.
 
co
pi
es
/1
00
 n
g 
to
ta
l D
NA
v.
g.
 
co
pi
es
/1
00
 n
g 
to
ta
l D
NA
v.
g.
 
co
pi
es
/1
00
 n
g 
to
ta
l D
NA
v.
g.
 
co
pi
es
/1
00
 n
g 
to
ta
l D
NA
%
 tr
an
sd
uc
ed
 n
eu
ro
ns
0
Fold change
over AAV9
Fold change
over AAV9
Fold change
over AAV9
GFP
β-actin
AA
V9
.47
AA
V9
AA
V-A
S
a b
c
d f
e
Molecular Therapy vol. 24 no. 4 apr. 2016 729
© The American Society of Gene & Cell Therapy
Global CNS Gene Transfer and RNAi by AAV-AS
huntingtin gene.48 Currently, there is no treatment for this dev-
astating disease, but experimental RNAi49,50 and oligonucleotide51 
therapies have shown promising results. AAV-AS and AAV9 
vectors encoding GFP and an U6-driven artificial microRNA 
specific for mouse Htt (miRHtt) were infused systemically in 
C57BL/6 mice. The knockdown efficiency of this AAV-miRHtt 
construct was 93% in a transient transfection assay in cell cul-
ture (Supplementary Figure S6). Huntingtin mRNA and protein 
levels in CNS and liver were assessed at 4 weeks postinjection 
(Figure 5). AAV-AS vector resulted in 33–50% reduction in Htt 
mRNA in striatum, motor cortex, and spinal cord, and was better 
than AAV9 in all brain regions, but comparable in the spinal cord 
(Figure 5a). Conversely, AAV-AS was less potent than AAV9 in 
lowering Htt  mRNA in liver (Figure 5a). Western blot analysis 
of Htt protein levels corroborated the differences between AAV9 
and AAV-AS in the striatum, motor cortex and thalamus as well 
as in liver (Figure 5b). As anticipated, the reduction in Htt pro-
tein levels was inversely proportional to GFP protein levels, which 
indicates that higher CNS transduction efficiency leads to greater 
reduction in huntingtin mRNA and protein.
DISCUSSION
The enhanced CNS transduction properties of AAV-AS represent 
an important improvement from AAV9 toward the ultimate goal 
of achieving gene transfer to the majority of cells in the CNS, par-
ticularly neurons. The neuronal transduction efficiency of recently 
discovered capsids capable of crossing the adult BBB (such as 
AAVrh8 and AAVrh10) is not quantitatively higher than AAV9.25 
In contrast, the new AAV-AS vector described here is more effi-
cient than AAV9 at transducing neurons in striatum and cerebral 
cortex. In addition, transduced motor neurons are evident in the 
spinal cord of AAV-AS injected mice, in contrast to AAV9 used 
in these experiments and in prior work.24 Nonetheless, the CNS 
transduction profile of AAV9 in this study appears less robust 
than in previous publications,25,52 possibly due to the lower dose 
and the relatively weak intron-less promoter used in this study. 
While we are unable to completely exclude the possibility that the 
potency of our AAV9 vector is lower than those from other labo-
ratories, we believe this is unlikely a major factor in the results 
reported here because the AAV vectors were prepared by the 
same method and titers determined in the same qPCR reaction to 
Figure 4 Neuronal transduction in cat after systemic delivery of AAV-AS vectors. (a) Transduction of neurons in the cat brain after systemic deliv-
ery of AAV-AS vector (1.29 × 1013 vg). Representative images (left) show GFP-positive cells with neuronal morphology in various structures in the brain 
and spinal cord. Bar = 50 μm. (b) Double immunoﬂuorescence staining for GFP and NeuN (right) conﬁrm the neuronal identity of GFP-positive cells 
in brain and spinal cord. White arrows indicate examples of GFP-positive neurons. Bar = 50 μm.
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ensure that animals received comparable doses of the two vectors. 
Moreover, the CNS neuronal transduction profile of AAV-AS was 
also reproduced in a normal cat, although some differences such 
as the absence of transduced endothelium were apparent, which 
could be the result of variability in promoter efficiency across 
species. An important aspect to consider is that the widespread 
neuronal transduction profile of AAV-AS was achieved with a 
dose (5 × 1011 vg/mouse) approximately 8–10-fold lower than in 
previous studies characterizing the CNS tropism of AAV924 and 
other natural AAV capsids25 in adult mice. The extent of stria-
tal neuronal transduction far exceeds any previous publication 
with systemic delivery of any AAV capsid, regardless of dose. 
Nonetheless, it is important to note the neuronal transduction 
properties of this new AAV-AS capsid are not uniform across the 
brain as evidenced by the considerable difference in percentage of 
GFP-positive neurons between striatum and thalamus.
The variability in neuronal transduction with AAV-AS in dif-
ferent brain structures is likely to be determined by the CNS dis-
tribution of cell surface receptor(s) used by this new AAV vector 
to cross the BBB and transduce neurons. Glycans with terminal 
galactose have been identified as the primary factor for AAV9 
attachment to the cell surface46,47 and the galactose-binding domain 
Figure 5 Htt knockdown in mice upon intravenous administration of AAV-AS-miRHtt vector. (a) Changes in Htt mRNA levels in brain structures, 
cervical spinal cord and liver in wild-type mice injected systemically with AAV-AS or AAV9 vectors (n = 4 per group) (9.4 × 1011 vg/mouse) encoding 
a U6 promoter-driven artiﬁcial microRNA (miRHtt) targeting mouse huntingtin mRNA. Values for each region were normalized to Htt mRNA levels in 
age-matched phosphate buffer saline (PBS)-injected mice. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Student’s unpaired two-tailed t-test. 
Data shown is mean ± error. (b) Western blot analysis of Htt and GFP protein levels in brain structures, cervical spinal cord, and liver of the same AAV-
injected mice and PBS-injected controls. Values for each region were normalized to HTT protein levels in age-matched PBS-injected mice. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001 by Student’s unpaired two-tailed t-test. Data shown is mean ± SD.
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on the AAV9 capsid surface has been identified.53 Integrin bind-
ing appears to have a role in AAV9 transduction.54 Nonetheless, 
the mechanism that AAV9 and other AAV capsids use to cross 
the BBB, or cerebrospinal fluid-blood barrier as previously sug-
gested26 is presently unknown. To our knowledge, there is no evi-
dence suggesting that poly-alanine peptides target the CNS after 
vascular infusion, or are present in proteins such as transferrin 
or insulin that are known to cross the brain through transcytosis. 
The topological location of the N-terminus of AAV VP2 is uncer-
tain since there is no crystallographic information on the location 
of VP1 or VP2 proteins for any of the AAV capsids with charac-
terized structures.55,56 A recent study, however, indicates that the 
N-terminus of chimeric VP2 proteins is exposed on the capsid 
surface of at least 70% of capsids,43 suggesting this may also be the 
case for the poly-alanine peptide in AAV-AS. The results from our 
study on CHO cells show that cell surface binding of AAV-AS is 
identical to AAV9 and AAV9.47, suggesting the interaction with 
glycans with exposed terminal galactose residues is not affected by 
the poly-alanine peptide. The impact of the poly-alanine residues, 
however, on the interaction of AAV9.47 capsid with co-receptors 
on the luminal surface of brain microvascular endothelial cells or 
other cells along the BBB and cerebrospinal fluid-blood barrier is 
presently unknown. Further studies will be necessary to uncover 
the mechanism that underlies this increased efficiency.
The potential of AAV-AS for development of potent thera-
pies for neurological diseases is apparent by its efficacy in reduc-
ing huntingtin (Htt) mRNA by 40–50% in striatum and motor 
cortex—two structures relevant to HD pathophysiology—after 
a single systemic infusion. Earlier studies investigating direct 
striatal injection of AAV vectors encoding Htt-specific shRNA or 
microRNAs in adult mice have consistently reported no higher 
than 40–60% silencing of Htt mRNA at the injection site.49,50,57 
A recent study investigating the therapeutic efficacy of a systemi-
cally delivered AAV9-miR vector in HD mouse models was unable 
to demonstrate Htt mRNA knockdown in the brain of transgenic 
BACHD mice, and 33% mRNA knockdown in the striatum but 
no significant difference in the frontal cortex of N171-82Q mice 
upon administration of a higher dose,58 which agrees well with the 
extent of knockdown documented in this study with AAV9 vector.
There is an apparent discrepancy between the differential in 
GFP transduction efficiency of striatal neurons between AAV-AS 
and AAV9 vectors (36% versus <1 %) and the comparatively mod-
est increase in Htt knockdown in the same structure with AAV-
miRHtt vectors. It is key to note that knockdown is a sum effect of 
all transduced cells in a particular structure, and not just the neu-
ronal population. This is exemplified by the comparatively smaller 
6–15-fold increase in AAV-AS transduction compared to AAV9 
when measured by vector genome quantification, where the con-
tribution of every transduced CNS cell is taken into account. This 
could indicate that AAV9 transduces other cell types to some 
extent, but the resulting GFP expression level from the CBA pro-
moter used in this study is below the detection limit of our immu-
nohistochemical staining. By the same measure, it is possible the 
degree of enhancement of neuronal transduction between the 
two vectors may not be as large as suggested by the histological 
quantification results. Importantly, as mentioned above, AAV-
mediated Htt silencing in the striatum after direct injection has 
been reported at a maximum of 40–60%, even at the site of local 
injection where the percentage of transduced cells is very high. 
The reasons for this maximum effect are unknown at the moment, 
but could be due to only a fraction of Htt mRNA in CNS cells 
being accessible to the RNAi pathway. Therefore, the 33–50% 
reduction documented by systemic infusion of AAV-AS is likely 
to be near or at the maximum Htt silencing possible with AAV 
vectors engaging the RNAi pathway in the brain, irrespective of 
any further gene transfer efficacy. The use of differing promoters 
and vector doses further confounds drawing any direct quantita-
tive correlation between the two experiments.
The reduction in Htt mRNA across the brain achieved with 
AAV-AS makes it a promising new platform for development of 
a global gene therapy approach for Huntington’s disease as well 
as other neurological diseases affecting broadly distributed neu-
ronal populations, including amyotrophic lateral sclerosis (ALS), 
frontotemporal dementia and Rett syndrome, among others. In 
conclusion, AAV-AS is the first AAV capsid with superior CNS 
gene transfer properties since the discovery of AAV9 and provides 
a potent new platform for development of novel gene therapies for 
neurological diseases.
MATERIALS AND METHODS
Generation of packaging constructs. AAV9.47 trans packaging plasmid 
was generated by replacing a portion of the AAV9 cap sequence in pack-
aging plasmid pAR-9 with a de novo synthesized fragment carrying the 
following mutations S414N, G453D, K557E and T582I described in the 
original work44 (GenScript USA, Piscataway, NJ) (amino acid numbering 
beginning at VP1) using In-Fusion cloning kit (Clontech Laboratories, 
Mountain View, CA). Packaging plasmid necessary to express either only 
VP1 and VP3 capsid proteins, or VP2 protein fused to peptide were gen-
erated by introducing point mutations (T138A substitution to generate 
VP1,3 plasmids; M1L for VP2 plasmids) as described for AAV2.45 Peptide 
and linker (G4S) coding sequences were cloned at the N-terminus of VP2 
using In-Fusion cloning kit to generate peptide-VP2 expression plasmids.
Vector particle production, titer quantiﬁcation, and quality analysis. The 
self-complementary AAV-CBA-GFP vector used in these studies carries an 
expression cassette comprised of the CBA promoter without an intron to 
drive expression of GFP and a rabbit β-globin poly-adenylation signal.26
Sequences targeting mouse Htt mRNA were embedded into the ar-
tificial miR-155 scaffold to generate the following cassette: 5′-ctggag 
gcttgctgaaggctgtatgctgTTTAGACTTGTGTCCTTGACCTgttttggccactg 
actgacTGGCAAAGCACAAGTCTAAAcaggacacaaggcctgttactagcactcac 
atggaacaaatggcc-3′ (targeting sequence in bold uppercase). This artificial 
miRNA targets position 1090 in exon 8 of mouse huntingtin gene. eGFP 
and artificial miRNA cassette were expressed under the control of the cy-
tomegalovirus enhancer/chicken β-actin promoter containing the β-actin 
exon and chimeric intron.
To generate peptide-grafted AAV vectors, 293T cells were cotransfected 
with the following mix of plasmids using the calcium phosphate 
precipitation method: 7.96 μg transgene plasmid, 25.6 μg adenoviral helper 
plasmid pFΔ6, and a 5:1 ratio of VP1,3 packaging plasmid and peptide-
VP2 packaging fused expression plasmid in trans, for a total amount of 
12.2 μg, per 2.1 × 107 cells plated. Seventy-two hours post-transfection, 
cells were harvested and cell lysates prepared by three cycles of freeze-thaw 
and treated with Benzonase (Sigma-Aldrich, St. Louis, MO) (50 U/ml cell 
lysate, 37 °C, 30 minutes). rAAV was purified from cell lysates by iodixanol 
density-gradient ultracentrifugation59 (Optiprep density gradient medium, 
Axis-Shield, Oslo, Norway). Residual iodixanol was removed by replacing 
with Buffer B (20 mmol/l TRIS, 0.5 M NaCl, pH 8.5) using a 100 kilodalton 
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(kDa) cutoff centrifugation device (Amicon Ultra-15, Merck Millipore, 
Cork, Ireland) by three rounds of centrifugation at 1,500× g and dialyzed 
twice using a 10,000 molecular weight cutoff dialysis cassette (Slide-A-
Lyzer, Thermo Scientific, Rockford, IL) against a 1,000-fold volume of 
phosphate buffer saline (PBS) for >2 hours and once overnight at 4  °C. 
After treatment of stocks with DNase I (Roche Diagnostics GmbH, 
Mannheim, Germany, 2 U/μl vector, 37 °C, 30 minutes), the titer of rAAV 
vectors was determined by real-time quantitative PCR (qPCR) using probe 
and primers specific for the rabbit β-globin polyA sequence (Integrated 
DNA Technologies, Coralville, IA). For stoichiometric analysis of capsid 
proteins, 1 × 1010 vector particles of purified vector were subjected to 
western blotting by standard SDS-PAGE technique. AAV capsid proteins 
were detected using mouse monoclonal anti-AAV capsid protein antibody 
clone B1 (1:500, American Research Products, Waltham, MA, 03-65158), 
peroxidase-linked anti-mouse secondary antibody (1:2,000, GE Healthcare 
UK, Buckinghamshire, UK, 380199) and ECL Western Blotting Substrate 
(Pierce Protein Research Products, Rockford, IL).
Vector administration and tissue processing. The Institutional Animal 
Care and Use Committees at the University of Massachusetts Medical 
School and Auburn University reviewed and approved all experiments 
in mice and cats, respectively, in compliance with guidelines from the 
National Institutes of Health (Bethesda, MD).
rAAV vectors were administered via the tail vein in a volume of 200 μl 
into 6–8-week-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, 
ME). A dose of 5 × 1011 vg/mouse was administered for immunochemical 
studies and biodistribution analysis.
For immunochemical and GFP fluorescence studies, mice were 
trans-cardially perfused at 4 weeks postinjection first with ice cold 1× 
PBS, followed by 4% paraformaldehyde solution (Fisher Scientific, Fair 
Lawn, NJ). Tissues were harvested and postfixed in 4% paraformaldehyde 
solution at 4 °C for an additional 24 hours. Postfixed tissues were 
transferred to 30% sucrose in 1× PBS for cryoprotection. Tissues were 
embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, 
CA) and frozen in a dry-ice-isopentane bath and stored at −80 °C.
For biodistribution analysis, mice were trans-cardially perfused 
at 4 weeks postinfusion with ice-cold 1× PBS. Tissues were harvested 
immediately, frozen on dry ice and stored at −80 °C.
Cat studies. rAAV vector was packaged by University of Massachusetts 
Medical School Viral Vector Core by transient transfection followed by puri-
fication by cesium chloride sedimentation,60,61 and administered through 
the carotid artery into a 2-month-old normal domestic short haired cat at 
a dose of 1.29 × 1013 vg. The cat was not screened for pre-existing anticap-
sid neutralizing antibodies. At 4 weeks postinfusion, the injected cat was 
trans-cardially perfused with cold 1× PBS. Various tissues were harvested 
and fixed in 4% paraformaldehyde in PBS at 4 °C. The brain was cut into 
0.6 cm coronal blocks prior to immersion in fixative. Processing of postfixed 
brains and spinal cords for immunohistochemical (IHC) and immunofluo-
rescence studies was identical to that for mouse studies.
Immunohistochemical detection of GFP expression. For chromogenic 
IHC, 40 μm serial sections of brains and 30 μm serial sections of spinal cord 
were incubated for 96 hours in anti-GFP primary antibody (ABfinity rab-
bit monoclonal anti-GFP 1:1,000, G10362, Life Technologies, Grand Island, 
NY), or overnight in anti-GFAP (rabbit polyclonal anti-GFAP 1:500, Z0334, 
Dako, Glostrup, Denmark) or anti-Iba1 (rabbit polyclonal anti-Iba1 1:1,000, 
019-19741, Wako, Osaka, Japan) at 4 °C. After washing with 1× PBS, sections 
were incubated in appropriate biotinylated secondary antibody (biotinyl-
ated anti-rabbit antibody, Vector Laboratories, Burlingame, CA), followed 
by incubation in ABC reagent (PK-6100, Vector Laboratories). Sections 
were developed with 3,3′-diaminobenzidine reagent (DAB) according to 
the manufacturer’s instructions (SK-4100, Vector Laboratories), dehydrated 
with increasing concentrations of ethanol, cleared with xylene and mounted 
using Permount mounting medium (Fisher Scientific).
For immunofluorescence studies, 40 μm sections of brains and 30 
μm sections of spinal cord were incubated for 24 hours in a cocktail of 
appropriate primary antibodies at 4 °C. The primary antibodies used were: 
rabbit polyclonal anti-GFP (1:1,000, Life Technologies, Grand Island, NY, 
A11122), mouse monoclonal anti-NeuN (1:500, EMD Millipore, Billerica, 
MA, MAB377), mouse monoclonal anti-DARPP32 (1:250, BD Biosciences, 
Franklin Lakes, NJ, 611520), mouse monoclonal anti-GFAP (1:500, 
Abcam, Cambridge, MA, ab4648). After washing in 1× PBS, sections 
were incubated for 1 hour at room temperature in appropriate secondary 
antibodies, washed in 1× PBS and mounted using Permafluor mounting 
media (Thermo Scientific). Native GFP fluorescence in liver and skeletal 
muscle (quadriceps) was analyzed in 30 μm sections mounted using 
Permafluor mounting media. All images were captured on a Leica DM5500 
B microscope (Leica Microsystems, Buffalo Grove, IL). Postprocessing of 
images was performed using Adobe Photoshop CS6 (Adobe Systems, San 
Jose, CA).
Quantiﬁcation of GFP-positive neurons in striatum and thalamus. 
Chromogenic IHC staining of 40 μm mouse brain sections was performed 
as described in an earlier section. Five 663.28 × 497.40 μm regions were 
randomly chosen from the striatum or thalamus (n =4 biological replicates 
per vector) of the stained sections. Neurons were identified by their mor-
phology and counted by individuals blinded to the study design. All statis-
tical analyses were performed using GraphPad Prism (GraphPad Software, 
La Jolla, CA). Total neurons in the 663.28 × 497.40 μm fields were counted 
in Nissl (cresyl violet acetate) stained brain sections using ImageJ software. 
Significance was determined by Student’s unpaired two-tailed t-test. A 
P <  0.05 was considered to be significant.
Biodistribution analysis. Vector genome copy numbers from various 
mouse tissues were determined by qPCR after extraction of total DNA 
using DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). Tissues 
were mechanically lysed using TissueLyzer II (Qiagen). Vector genome 
content in each tissue was determined using 100 ng total DNA using the 
same qPCR method described above for AAV vector titration using a plas-
mid-based standard curve, and a viral vector internal control for quality 
assurance. All statistical analyses were performed using GraphPad Prism. 
Significance was determined by Student’s unpaired two-tailed t-test. A P < 
0.05 was considered to be significant.
Western blotting to detect GFP protein levels in various tissue 
types was performed using primary antibodies detecting GFP (chicken 
polyclonal anti-GFP, 1:2,000, Aves Labs, Tigard, OR, GFP-1010) and 
mouse β-actin (mouse monoclonal anti-β-actin, 1:1,000, Sigma-Aldrich, 
A5441), followed by appropriate IRDye secondary antibodies (LI-COR, 
Lincoln, NE). Total protein was isolated from harvested tissues by bead 
lysis in T-PER tissue extraction reagent (Life Technologies) and quantified 
by Bradford assay (Bio-Rad, Hercules, CA). Twenty micrograms of total 
protein were loaded onto each well of 4–20% Mini-PROTEAN TGX gels 
(Bio-Rad). Tissues from two representative mice per group were used for 
analysis. Detection and quantification were done with Odyssey infrared 
imaging system (LI-COR).
In vitro binding assay. Pro5 and Lec2 CHO cell lines were gifts from Dr. 
Aravind Asokan (University of North Carolina Chapel Hill) and binding 
assay was performed as previously described.46 Briefly, cells were prechilled 
for 30 minutes at 4 °C in serum-free DMEM (Life Technologies), followed 
by incubation with rAAV vectors at 4 × 104 vg/cell in cold serum-free 
media DMEM at 4 °C. Ninety minutes later, cells were washed thrice with 
cold serum-free DMEM to remove loosely bound vector particles. Cells 
were harvested and total DNA was extracted using DNeasy Blood and 
Tissue kit (Qiagen). Vector genome copy numbers of cell surface bound 
virions was quantified by qPCR as described earlier.
In vitro knockdown assay. A 159 bp sequence containing the Htt mRNA 
target sequence was cloned into pSiCHECK-2 vector (Promega, Madison, 
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WI) between the XhoI and NotI restriction sites in the 3’ UTR of the Renilla 
luciferase gene. Luciferase assays were performed by cotransfection in 
24-well plates with 0.025 μg/well of the Htt target-containing pSiCHECK-2 
reporter and 0.6 μg/well of GIPZ or AAV transgene plasmid contain-
ing either Htt targeting- artificial miRNA sequence (miRHtt) or scrambled 
miRNA sequence. Transfections were performed using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA), according to the manufacturer’s protocol. Forty-
eight hours after transfection, the cells were lysed for 20 minutes in 1× passive 
lysis buffer (Promega). Luciferase activity was read in 96-well plates with the 
Dual-luciferase assay kit (Promega) using the GloMax multi-detection sys-
tem (Promega). Renilla luciferase values were normalized for intraplasmid 
transfection efficacy to firefly luciferase signal. All statistical analyses were 
performed using GraphPad Prism. Significance was determined by Student’s 
unpaired two-tailed t-test. A P < 0.05 was considered to be significant.
Analysis of in vivo Htt knockdown. rAAV vectors were administered intra-
vascularly via the tail vein into 6–8-week-old male C57BL/6J mice (Jackson 
Laboratory, Bar Harbor, ME) at a dose of 9.4 × 1011 vg/mouse. Mice were 
euthanized at 4 weeks postinjection and the brain sectioned in 2 mm coro-
nal blocks using a brain matrix. Biopsy punches of different diameters (2 
or 3 mm) were used to sample motor cortex (2 mm), striatum (3 mm), 
and thalamus (3 mm). Cervical spinal cord and liver were also included 
in the analysis. Tissue samples were mechanically homogenized using 
a TissueLyzer II and 5 mm stainless steel beads (Qiagen) in Trizol (Life 
Technologies). Total RNA was isolated using Direct-zol RNA MiniPrep 
kit (Zymo Research Corporation, Irvine, CA) according to manufacturer’s 
protocol. Total RNA (400–1,000 ng) was reverse transcribed using High 
Capacity RNA to cDNA kit (Applied Biosystems, Foster City, CA). Relative 
mouse Htt mRNA expression was assessed by qPCR using TaqMan gene 
expression assays for mouse Htt (Mm01213820_m1, Applied Biosystems) 
and hypoxanthine phosphoribosyltransferase 1 (Hprt1; mm00446968_m1, 
Applied Biosystems). Changes in Htt mRNA for groups injected with AAV9 
or AAV-AS vectors were calculated relative to PBS-injected mice using the 
2-ΔΔCT method.62 Significance was determined by Student’s unpaired two-
tailed t-test. A P < 0.05 was considered to be significant.
For protein analysis, a frozen punch from each region (motor cortex, 
striatum, thalamus, cervical spinal cord, and liver) was homogenized in 
75–300 μl 10 mmol/l HEPES pH7.4, 250 mmol/l sucrose, 1 mmol/l EDTA 
+ protease inhibitor tablet (cOmplete mini, EDTA-free, Roche), 1 mmol/l 
NaF, and 1 mmol/l Na3VO4 on ice for 30 strokes. Protein concentration was 
determined by Bradford method (BioRad) and 10 μg motor cortex, striatum, 
and thalamus or 20 μg cervical spinal cord and liver were loaded onto 3–8% 
Tris-Acetate gels (Life Technologies) and separated by SDS-PAGE. Proteins 
were transferred to nitrocellulose using a TransBlot Turbo apparatus (Bio-
Rad) then blots were cut horizontally at 72 kD. Blots were washed in TRIS-
buffered saline + 0.1% Tween 20 (TBST) and blocked in 5% milk/TBST. 
The top half of the blot was incubated in anti-Htt antibody Ab163 (1:2,000) 
and the bottom half in anti-tubulin antibody (1:4,000, Sigma-Aldrich) 
or anti-GAPDH antibody (1:6,000, Millipore) diluted in 5% milk/TBST 
overnight at 4 °C. Blots were washed in TBST then incubated in peroxidase 
conjugated secondary antibodies diluted in 5% milk/TBST for 1 hour at room 
temperature, washed, and proteins were detected using SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific) and FluoroChem SP 
(Alpha Innotech) and Hyperfilm ECL (GE Healthcare). The bottom blots 
were reprobed with anti-GFP antibody (1:3,000, Cell Signaling Technologies, 
Danvers, MA). Densitometry was performed using ImageJ software.
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